These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

902 related articles for article (PubMed ID: 33571241)

  • 1. In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses.
    Castro A; Ozturk K; Zanetti M; Carter H
    PLoS One; 2021; 16(2):e0246731. PubMed ID: 33571241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC-II constrains the natural neutralizing antibody response to the SARS-CoV-2 spike RBM in humans.
    Castro A; Ozturk K; Zanetti M; Carter H
    bioRxiv; 2020 Dec; ():. PubMed ID: 33398284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Landscape and selection of vaccine epitopes in SARS-CoV-2.
    Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A
    Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern.
    Voss C; Esmail S; Liu X; Knauer MJ; Ackloo S; Kaneko T; Lowes L; Stogios P; Seitova A; Hutchinson A; Yusifov F; Skarina T; Evdokimova E; Loppnau P; Ghiabi P; Haijan T; Zhong S; Abdoh H; Hedley BD; Bhayana V; Martin CM; Slessarev M; Chin-Yee B; Fraser DD; Chin-Yee I; Li SS
    JCI Insight; 2021 Jul; 6(13):. PubMed ID: 34081630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and Validation of Peptides Specifying SARS-CoV-2 B-Cell Epitopes Eliciting Neutralizing Antibodies.
    Poh CL; Yahaya AAAB; Cheong HT; Lim HX
    Methods Mol Biol; 2024; 2821():165-177. PubMed ID: 38997488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research.
    Chen Z; Ruan P; Wang L; Nie X; Ma X; Tan Y
    J Cell Mol Med; 2021 Jan; 25(2):1274-1289. PubMed ID: 33325143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients.
    Zhang Y; Yang Z; Tian S; Li B; Feng T; He J; Jiang M; Tang X; Mei S; Li H; Zhong Y; Li G; Tang M; Liu S; Tang T; Wang C; Wang X
    BMC Microbiol; 2021 Jun; 21(1):194. PubMed ID: 34174835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein.
    Chukwudozie OS; Gray CM; Fagbayi TA; Chukwuanukwu RC; Oyebanji VO; Bankole TT; Adewole RA; Daniel EM
    PLoS One; 2021; 16(3):e0248061. PubMed ID: 33730022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals.
    Yoshida S; Ono C; Hayashi H; Fukumoto S; Shiraishi S; Tomono K; Arase H; Matsuura Y; Nakagami H
    Sci Rep; 2021 Mar; 11(1):5934. PubMed ID: 33723294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-Predicted MHC Class II Epitope Presentation of SARS-CoV-2 Structural Proteins Correlates to the Case Fatality Rates of COVID-19 in Different Countries.
    Liang C; Bencurova E; Psota E; Neurgaonkar P; Prelog M; Scheller C; Dandekar T
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seropositive Reaction Rates of 9 B-Cell Epitopes of the SARS-CoV-2 Spike Protein and the Relationship between the Epitopes and Neutralizing Antibody.
    Zhu L; Zhang Y; Yang Z; Li B; Feng T; Zou X; He J; He T; Li J; Liu N; Li W; Wang X
    Intervirology; 2022; 65(1):29-36. PubMed ID: 34233324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.
    Makdasi E; Levy Y; Alcalay R; Noy-Porat T; Zahavy E; Mechaly A; Epstein E; Peretz E; Cohen H; Bar-On L; Chitlaru T; Cohen O; Glinert I; Achdout H; Israely T; Rosenfeld R; Mazor O
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33810465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
    Yao L; Wang GL; Shen Y; Wang ZY; Zhan BD; Duan LJ; Lu B; Shi C; Gao YM; Peng HH; Wang GQ; Wang DM; Jiang MD; Cao GP; Ma MJ
    J Infect Dis; 2021 Aug; 224(4):586-594. PubMed ID: 33978754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.